Erlotinib has been shown to improve progression-free survival and, in some cases, overall survival in patients with EGFR-mutant NSCLC. It offers a targeted approach, which can be more effective and have fewer side effects compared to traditional chemotherapy. For pancreatic cancer, when used with gemcitabine, it can offer modest improvements in survival.
